Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science…
Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease
In Canada, lecanemab is indicated for the treatment of adult patients with…
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
October 26, 2025 19:15 ET | Source: Vivani Medical, Inc. ALAMEDA, Calif.,…
Indigenously Designed and Manufactured Laptops by Vyonix Launched at IMC 2025
GURUGRAM, India, Oct. 27, 2025 /PRNewswire/ -- India's 1st indigenously designed and…
Xinhua Silk Road: China’s Langjiu holds “Chinese Langjiu, Welcoming the World” event in Italy
BEIJING, Oct. 27, 2025 /PRNewswire/ -- Langjiu, a leading Chinese baijiu brand,…
Credit Blockchain Brings AI Computing to the Forefront, Targeting Stability Amid Crypto Turbulence
London, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Credit Blockchain, a global leader…
Hohem Lands in Best Buy Stores with AI Gimbals
NEW YORK, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Hohem, a global leader…
New Crypto Mutuum Finance (MUTM) Announces V1 Protocol as Investor Count Tops 17,400
Dubai, UAE, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Ethereum remains at the…
Avacta presents first preclinical data from dual payload pre|CISION medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a…
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT…
